Molecular Neurobiology, Год журнала: 2025, Номер unknown
Опубликована: Апрель 1, 2025
Язык: Английский
Molecular Medicine, Год журнала: 2025, Номер 31(1)
Опубликована: Фев. 21, 2025
Abstract Mesenchymal stem cells (MSCs) have emerged as a promising therapeutic strategy in regenerative medicine, demonstrating significant potential for clinical applications. Evidence suggests that MSCs not only exhibit multipotent differentiation but also exert critical effects retinal degenerative diseases via robust paracrine mechanisms. protect from damage by modulating inflammation, inhibiting apoptosis, alleviating oxidative stress, and suppressing cell death pathways. Furthermore, contribute to structural functional stability facilitating vascular remodeling donating mitochondria cells. Of particular interest, MSC-derived exosomes gained widespread attention compelling cell-free therapy. Owing their potent anti-inflammatory, anti-apoptotic, vascular-stabilizing properties, show promise the treatment of diseases.
Язык: Английский
Процитировано
1
Cancers, Год журнала: 2025, Номер 17(3), С. 383 - 383
Опубликована: Янв. 24, 2025
Anti-CD19 chimeric antigen receptor (CAR) T-cell therapy represents a breakthrough in the treatment of relapsed and refractory B-cell malignancies, such as chronic lymphocytic leukemia (CLL), inducing long-term, sometimes curative, responses. However, fewer than 30% CLL patients achieve outcomes. It has been shown that smaller subset T cells capable expansion persistence is crucial for effectiveness. Notably, pre-existing mutation epigenetic regulator TET2, combined with CAR vector-induced disruption other intact allele, significantly enhanced potency CAR-engineered clone one patient. This finding aligns independent research, suggesting gene’s genomic insertion site influences tumor-targeting capability. Thus, it plausible gene disruptions affect function. review synthesizes existing knowledge on vector integration into host genome its impact clinical outcomes patients. Our aim to inform development improved therapies enhance their overall efficacy.
Язык: Английский
Процитировано
0
Biomedicines, Год журнала: 2025, Номер 13(3), С. 758 - 758
Опубликована: Март 20, 2025
On 4 September 2024, the Reagan-Udall Foundation for FDA (FDA Foundation) in collaboration with Food and Drug Administration (FDA) Gates hosted a workshop titled “Scientific Advancements Gene Therapies: Opportunities Global Regulatory Convergence”. The event brought together diverse group of experts, including international regulatory bodies, regulated industries, healthcare professionals, patients, academic researchers global health advocates, to discuss rapid advancements gene therapy pressing need equitable access low-and middle-income countries (LMICs), sickle cell disease (SCD) serving as model disorder discussions. Although there has been significant progress therapy, such breakthroughs clustered regularly interspaced short palindromic repeats (CRISPR)-based technologies FDA-approved therapies, these therapies remain limited underresourced regions. addressed critical challenges, high cost gaps barriers ethical concerns regarding informed consent public engagement LMICs. This paper highlights discussion points from focus on exploring strategies convergence, role collaborations potential pathways making affordable accessible all.
Язык: Английский
Процитировано
0
Biochemical Pharmacology, Год журнала: 2025, Номер unknown, С. 116902 - 116902
Опубликована: Март 1, 2025
Язык: Английский
Процитировано
0
Molecular Neurobiology, Год журнала: 2025, Номер unknown
Опубликована: Апрель 1, 2025
Язык: Английский
Процитировано
0